These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 38824627)

  • 1. Iptacopan and danicopan for paroxysmal nocturnal hemoglobinuria.
    Fahim SM; Makam AN; Suh K; Carlson JJ; Richardson M; Herce-Hagiwara B; Dickerson R; Pearson SD; Agboola F
    J Manag Care Spec Pharm; 2024 Jun; 30(6):618-623. PubMed ID: 38824627
    [No Abstract]   [Full Text] [Related]  

  • 2. Addition of iptacopan, an oral factor B inhibitor, to eculizumab in patients with paroxysmal nocturnal haemoglobinuria and active haemolysis: an open-label, single-arm, phase 2, proof-of-concept trial.
    Risitano AM; Röth A; Soret J; Frieri C; de Fontbrune FS; Marano L; Alashkar F; Benajiba L; Marotta S; Rozenberg I; Milojevic J; End P; Nidamarthy PK; Junge G; Peffault de Latour R
    Lancet Haematol; 2021 May; 8(5):e344-e354. PubMed ID: 33765419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor B inhibitor iptacopan for the treatment of paroxysmal nocturnal hemoglobinuria.
    Xu B; Kang B; Chen J; Li S; Zhou J
    Blood Rev; 2024 Jul; 66():101210. PubMed ID: 38811284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 study of danicopan in patients with paroxysmal nocturnal hemoglobinuria with an inadequate response to eculizumab.
    Kulasekararaj AG; Risitano AM; Maciejewski JP; Notaro R; Browett P; Lee JW; Huang M; Geffner M; Brodsky RA
    Blood; 2021 Nov; 138(20):1928-1938. PubMed ID: 34314483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The first successful expanded compassionate use of Iptacopan in a patient with paroxysmal nocturnal hemoglobinuria.
    Han B; Ji J; Zhang B; Bai H; Zhou D; Feng F; Huang Y; Zhu H; Chen L; Wu Z; Jiang X; Li X; Jia Q; Chang Q; Pan H; Peng H; Zheng W; Huang H; Chen Z; Yang C; Chen M; Du B; Zhang S
    Ann Hematol; 2022 Nov; 101(11):2537-2539. PubMed ID: 35965286
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria. Reply.
    Risitano AM; Kulasekararaj AG; Peffault de Latour R
    N Engl J Med; 2024 Jun; 390(21):2033-2034. PubMed ID: 38838321
    [No Abstract]   [Full Text] [Related]  

  • 7. Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.
    Marnas P; Zarogiannis SG
    N Engl J Med; 2024 Jun; 390(21):2033. PubMed ID: 38838320
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral Iptacopan in Paroxysmal Nocturnal Hemoglobinuria.
    Hillmen P
    N Engl J Med; 2024 Jun; 390(21):2032-2033. PubMed ID: 38838319
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral Iptacopan Monotherapy in Paroxysmal Nocturnal Hemoglobinuria.
    Peffault de Latour R; Röth A; Kulasekararaj AG; Han B; Scheinberg P; Maciejewski JP; Ueda Y; de Castro CM; Di Bona E; Fu R; Zhang L; Griffin M; Langemeijer SMC; Panse J; Schrezenmeier H; Barcellini W; Mauad VAQ; Schafhausen P; Tavitian S; Beggiato E; Chew LP; Gaya A; Huang WH; Jang JH; Kitawaki T; Kutlar A; Notaro R; Pullarkat V; Schubert J; Terriou L; Uchiyama M; Wong Lee Lee L; Yap ES; Sicre de Fontbrune F; Marano L; Alashkar F; Gandhi S; Trikha R; Yang C; Liu H; Kelly RJ; Höchsmann B; Kerloeguen C; Banerjee P; Levitch R; Kumar R; Wang Z; Thorburn C; Maitra S; Li S; Verles A; Dahlke M; Risitano AM
    N Engl J Med; 2024 Mar; 390(11):994-1008. PubMed ID: 38477987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Iptacopan: First Approval.
    Syed YY
    Drugs; 2024 May; 84(5):599-606. PubMed ID: 38517653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Danicopan: First Approval.
    Kang C
    Drugs; 2024 May; 84(5):613-618. PubMed ID: 38528310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy.
    Versino F; Fattizzo B
    Int J Lab Hematol; 2024 May; 46 Suppl 1():43-54. PubMed ID: 38622956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial.
    Lee JW; Griffin M; Kim JS; Lee Lee LW; Piatek C; Nishimura JI; Carrillo Infante C; Jain D; Liu P; Filippov G; Sicre de Fontbrune F; Risitano A; Kulasekararaj AG;
    Lancet Haematol; 2023 Dec; 10(12):e955-e965. PubMed ID: 38030318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study.
    Jang JH; Wong L; Ko BS; Yoon SS; Li K; Baltcheva I; Nidamarthy PK; Chawla R; Junge G; Yap ES
    Blood Adv; 2022 Aug; 6(15):4450-4460. PubMed ID: 35561315
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Danicopan: an oral complement factor D inhibitor for paroxysmal nocturnal hemoglobinuria.
    Risitano AM; Kulasekararaj AG; Lee JW; Maciejewski JP; Notaro R; Brodsky R; Huang M; Geffner M; Browett P
    Haematologica; 2021 Dec; 106(12):3188-3197. PubMed ID: 33121236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel anti-complement therapeutics for hemolytic anemia].
    Nishimura JI
    Rinsho Ketsueki; 2023; 64(6):466-473. PubMed ID: 37407469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
    Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
    Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paroxysmal nocturnal hemoglobinuria clones in severe aplastic anemia patients treated with horse anti-thymocyte globulin plus cyclosporine.
    Scheinberg P; Marte M; Nunez O; Young NS
    Haematologica; 2010 Jul; 95(7):1075-80. PubMed ID: 20595102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cerebral sinus thrombosis and heparin-induced thrombocytopenia in a patient with paroxysmal nocturnal hemoglobinuria.
    Ishihara-Kawase K; Ohtsuki T; Sugihara S; Tanaka H; Nakamura T; Kimura A; Matsumoto M
    Intern Med; 2010; 49(10):941-3. PubMed ID: 20467181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring treatment strategies for paroxysmal nocturnal hemoglobinuria: an overview of registered clinical trials.
    Peixoto VP; Prudêncio C; Vieira M
    Curr Med Res Opin; 2024 May; ():1-11. PubMed ID: 38727420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.